

Is Absorica in shortage in 2026? Get the latest update on Absorica availability, pricing, and what patients can do to find their medication in stock.
If you're having trouble finding Absorica at your pharmacy, you're probably wondering: is there an actual shortage? The short answer is that Absorica is not currently listed on the FDA or ASHP drug shortage lists. But that doesn't mean it's easy to find.
Many patients across the country report difficulty filling their Absorica prescriptions — not because of a manufacturing shortage, but because of a combination of factors that limit availability at the pharmacy level. In this update, we'll break down the current situation and explain what you can do.
As of early 2026, there is no official national shortage of Absorica or generic Isotretinoin. The FDA's drug shortage database and the American Society of Health-System Pharmacists (ASHP) do not list Isotretinoin products as being in short supply.
However, patients regularly experience what feels like a shortage due to:
So while the medication exists in the supply chain, it may not be sitting on the shelf at your local pharmacy when you need it.
There are several interconnected reasons:
All Isotretinoin products are dispensed through iPLEDGE, the FDA's Risk Evaluation and Mitigation Strategy. This program requires monthly patient check-ins, pregnancy testing for patients who can become pregnant, and strict verification before each fill. Pharmacies must be registered with iPLEDGE to dispense the medication, and not all are.
The 7-day dispensing window means that if a pharmacy doesn't have Absorica in stock when your window opens, you may not have enough time to get it ordered and delivered before your authorization expires.
Brand-name Absorica costs $300 to $1,600 per month without insurance, while generic Isotretinoin costs $50 to $200 with a discount card. Most insurance companies require patients to use generics first (step therapy), so pharmacies stock generics much more heavily than brand-name Absorica.
In December 2021, the iPLEDGE system transitioned to a new online platform, causing weeks of dispensing disruptions across the country. While the system has since stabilized, the experience highlighted how dependent Isotretinoin access is on a single digital platform. Periodic technical glitches can still cause delays.
Cost remains a significant factor in accessibility:
Sun Pharma offers a manufacturer savings card for commercially insured patients, and a Patient Assistance Program for uninsured or underinsured patients. For a full breakdown of savings options, check our guide on how to save money on Absorica.
The Isotretinoin landscape continues to evolve:
For patients exploring non-Isotretinoin options, alternatives like Spironolactone (for hormonal acne in women) and Doxycycline may be worth discussing with your doctor. See our full guide on alternatives to Absorica.
If you need Absorica specifically, here's your action plan:
For a detailed walkthrough, read our guide on how to find Absorica in stock near you.
There is no official Absorica shortage in 2026, but real-world availability challenges persist. The iPLEDGE program, insurance dynamics, and pharmacy stocking practices combine to make finding brand-name Absorica harder than it should be.
Stay proactive: use Medfinder before each refill, build a relationship with a reliable pharmacy, and explore savings programs to keep costs manageable. Your dermatologist is your best ally in navigating these challenges — don't hesitate to ask them for help.
For more on what this medication is and how it works, visit our guide on Absorica uses, dosage, and what you need to know.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.